During the past decade, Desert Hematology Oncology Medical Group, Inc. conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 15 clinical trials were completed, i.e. on average, 115.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Desert Hematology Oncology Medical Group, Inc." #1 sponsor was "Celgene" with 4 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Celgene Corporation" with 2 trials sponsored, "ImmunityBio, Inc." with 2 trials sponsored and "Nektar Therapeutics" with 2 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Desert Hematology Oncology Medical Group, Inc." #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "CIRION Central Laboratory" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "Dorevitch" with 1 trials as a collaborator and "ICON Clinical Research" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Desert Hematology Oncology Medical Group, Inc." are "Myelodysplastic Syndromes" (4 trials), "Breast Cancer" (3 trials), "Pancreatic Cancer" (3 trials), "Colorectal Cancer" (2 trials) and "Metastatic Breast Cancer" (2 trials). Many other conditions were trialed in "Desert Hematology Oncology Medical Group, Inc." in a lesser frequency.

Most popular intervention types in "Desert Hematology Oncology Medical Group, Inc." are "Drug" (41 trials), "Biological" (7 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "lenalidomide" (3 trials), "Azacitidine" (2 trials), "Carboplatin" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Desert Hematology Oncology Medical Group, Inc." are 31 trials for "All" genders, 6 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Desert Hematology Oncology Medical Group, Inc.". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Desert Hematology Oncology Medical Group, Inc., undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Desert Hematology Oncology Medical Group, Inc., 3 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".